Cargando…

Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?

Immunotherapy has considerably increased the number of anticancer agents in many tumor types including metastatic colorectal cancer (mCRC). Anti-PD-1 (programmed death 1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitors (ICI) have been shown to benefit the mCRC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Damilakis, Emmanouil, Mavroudis, Dimitrios, Sfakianaki, Maria, Souglakos, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225960/
https://www.ncbi.nlm.nih.gov/pubmed/32268531
http://dx.doi.org/10.3390/cancers12040889